Table 4.
Median and landmark survival outcomes
| Parameters | Pembrolizumab monotherapy (n = 20) | Sequential therapy (n = 20) | Concurrent therapy (n = 20) |
|---|---|---|---|
| EFS | |||
| Events to data cutt-off, na | 7 | 8 | 5 |
| Median EFS, months | NR | NR | NR |
| 12-month | |||
| EFS events, n | 4 | 4 | 4 |
| EFS rate, % (95% CI) | 80 (64, 100) | 80 (64, 100) | 80 (64, 100) |
| 24-month | |||
| EFS events, n | 7 | 4 | 5 |
| EFS rate, % (95% CI) | 60 (40, 89) | 80 (64, 100) | 71 (52, 98) |
| RFS | |||
| Events to data cut-off, nb | 5 | 4 | 8 |
| Median RFS, months | NR | NR | NR |
| 12-month | |||
| RFS events, n | 2 | 4 | 3 |
| RFS rate, % (95% CI) | 89 (75, 100) | 80 (64, 100) | 84 (69, 100) |
| 24-month | |||
| RFS events, n | 5 | 4 | 4 |
| RFS rate, % (95% CI) | 66 (45, 96) | 80 (64, 100) | 75 (55, 100) |
| OS | |||
| Deaths to data cut-off, n | 3 | 3 | 1 |
| Median OS, months | NR | NR | NR |
| 12-month | |||
| OS events, n | 1 | 1 | 1 |
| OS rate, % (95% CI) | 94 (84, 100) | 95 (85, 100) | 95 (85, 100) |
| 24-month | |||
| OS events, n | 3 | 2 | 1 |
| OS rate, % (95% CI) | 76 (55, 100) | 89 (75, 100) | 95 (85, 100) |
EFS, RFS and OS event numbers and landmark rates.
aEFS events include presurgical progression, postsurgical recurrence or death.
bRFS events include postsurgical recurrence or death.
NR, not reached.